{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1"},{"groupId":"OG001","value":"0.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"720"},{"groupId":"OG001","value":"740"}],"units":"Participants"}],"description":"Hepatotoxicity events were summarized by treatment arm. Hepatotoxicity events were assessed using liver function laboratory test (LFT) results which included the analysis of baseline and post-baseline levels of alanine transaminase (ALT), aspartate aminotransferase (AST), total bilirubin (TBILI), and alkaline phosphatase (ALK). Hepatic events, as adjudicated by the Hepatic Review Committee, are summarized. Percentages have been rounded off.","groups":[{"description":"Participants received trastuzumab, 6 mg/kg, IV, Q3W, as a maintenance dose for 14 cycles (1 cycle = 21 days) or until disease recurrence or unacceptable toxicity which ever occurs first.","id":"OG000","title":"Trastuzumab"},{"description":"Participants received trastuzumab emtansine, 3.6 mg/kg, IV, Q3W for 14 cycles (1 cycle = 21 days) or until disease recurrence or unacceptable toxicity which ever occurs first.","id":"OG001","title":"Trastuzumab Emtansine"}],"paramType":"NUMBER","populationDescription":"SE population included all randomized participants who received any amount of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to approximately 64 months","title":"Percentage of Participants With Hepatotoxicity Events as Adjudicated by the Hepatic Review Committee","type":"SECONDARY","unitOfMeasure":"percentage of participants"}